Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Metastatic Pancreatic Cancer
Related studies linked through entity extraction aliases.
BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
- Status
- COMPLETED
- Phase
- PHASE2
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
mFOLFIRINOX as First-Line Chemotherapy in Treating Chinese Patients With Metastatic Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
- Status
- TERMINATED
- Phase
- PHASE3
Phase I Study of TS-1 With Concurrent Radiotherapy to Treat Pancreatic Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer
- Status
- UNKNOWN
- Phase
- PHASE1
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE2
QYHJ Granules Versus Xeloda in Metastatic Pancreatic Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE1
BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study
- Status
- COMPLETED
- Phase
- PHASE1
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib
- Status
- UNKNOWN
- Phase
- PHASE2
BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1
- Status
- WITHDRAWN
- Phase
- PHASE2
Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.
- Status
- WITHDRAWN
- Phase
- PHASE1
A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment
- Status
- UNKNOWN
- Phase
- PHASE2
Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE3